The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

Biperiden (N04AA02)

Ebastin (R06AX22)

Formoterol & Beclometason (R03AK08)

Infliximab (L04AB02)

Loperamid (A07DA03)

Midazolam (N03AE02, N05CD08)

Nitisinon (A16AX04)

Paracetamol (N02BE01)

Perindopril & Amlodipine (C09BB04)

Tadalafil; only medicinal products for the treatment of benign prostate syndrome in adult men (C02KX07, G04BE08)

Tapentadol (N02AX06)

Tramadol & Paracetamol (N02AJ13)

Triptorelin (H01CA07, L02AE04)

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.01.2023. Based on this, the contract term is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest contract start is 01.01.2023. Based on this, the contract term is a maximum of 24 months.